Current Report Filing (8-k)
August 03 2021 - 9:48AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported): August 3, 2021
PAVMED
INC.
|
(Exact
Name of Registrant as Specified in Charter)
|
Delaware
|
|
001-37685
|
|
47-1214177
|
(State
or Other Jurisdiction
of
Incorporation)
|
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification
No.)
|
One
Grand Central Place, Suite 4600, New York, New York
|
|
10165
|
(Address
of Principal Executive Offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: (212) 949-4319
N/A
|
(Former
Name or Former Address, if Changed Since Last Report)
|
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).
|
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
Common
Stock, Par Value $0.001 Per Share
|
|
PAVM
|
|
The
Nasdaq Stock Market LLC
|
Series
Z Warrants to Purchase Common Stock
|
|
PAVMZ
|
|
The
Nasdaq Stock Market LLC
|
Series
W Warrants to Purchase Common Stock
|
|
PAVMW
|
|
The
Nasdaq Stock Market LLC
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company [X]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item
7.01.
|
Regulation
FD Disclosure.
|
On
August 3, 2021, PAVmed Inc. (the “Company”) issued a press release announcing that Aster Angagaw had joined the Board of Directors of its majority owned subsidiary Lucid Diagnostics Inc.
The
information furnished under this Item 7.01, including the exhibit related thereto, shall not be deemed “filed” for purposes
of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any disclosure document of
the Company, except as shall be expressly set forth by specific reference in such document.
Item
9.01.
|
Financial
Statements and Exhibits.
|
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Dated:
August 3, 2021
|
PAVMED
INC.
|
|
|
|
|
By:
|
/s/
Dennis M. McGrath
|
|
|
Dennis
M. McGrath
|
|
|
President
and Chief Financial Officer
|
PAVmed (NASDAQ:PAVMW)
Historical Stock Chart
From Sep 2024 to Oct 2024
PAVmed (NASDAQ:PAVMW)
Historical Stock Chart
From Oct 2023 to Oct 2024